Oral montelukast versus inhaled salmeterol to prevent exercise-induced bronchoconstriction.
Grieco
A J
AJ
Burstein-Stein
J
J
D000085:Acetates / Q000627:therapeutic use; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001250:Asthma, Exercise-Induced / Q000517:prevention & control*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D048448:Phenylcarbamates; D011804:Quinolines / Q000627:therapeutic use; D000068299:Salmeterol Xinafoate; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000009:adverse effects*
D000085:Acetates; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; D000068299:Salmeterol Xinafoate; C093875:montelukast; D000420:Albuterol; C062735:zafirlukast